Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome
Copyright © 2020 The Authors, some rights reserved. Fragile X syndrome is caused by FMR1 gene silencing and loss of the encoded fragile X mental retardation protein (FMRP), which binds to mRNA and regulates translation. Studies in the Fmr1-/y mouse model of fragile X syndrome indicate that aberrant...
Main Authors: | McCamphill, Patrick K, Stoppel, Laura J, Senter, Rebecca K, Lewis, Michael C, Heynen, Arnold J, Stoppel, David C, Sridhar, Vinay, Collins, Katie A, Shi, Xi, Pan, Jen Q, Madison, Jon, Cottrell, Jeffrey R, Huber, Kimberly M, Scolnick, Edward M, Holson, Edward B, Wagner, Florence F, Bear, Mark F |
---|---|
Format: | Article |
Language: | English |
Published: |
American Association for the Advancement of Science (AAAS)
2021
|
Online Access: | https://hdl.handle.net/1721.1/138160 |
Similar Items
-
Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome
by: McCamphill, Patrick K., et al.
Published: (2022) -
mGluR5 Negative Modulators for Fragile X: Treatment Resistance and Persistence
by: Stoppel, David C, et al.
Published: (2021) -
Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion
by: Tian, Di, et al.
Published: (2016) -
The Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
by: Bhakar, Asha, et al.
Published: (2016) -
β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X
by: Auerbach, Benjamin D., et al.
Published: (2017)